In the current Canadian treatment landscape for R/R DLBCL, CD19 chimeric antigen receptor T-cell (CAR-T) therapies have recently become available for patients eligible for HDT-ASCT with primary refractory DLBCL or a relapse within 12 months of 1L treatment. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.